Volkmann ER, Andréasson K, Smith V (2023) Systemic sclerosis. Lancet 401(10373):304–318. https://doi.org/10.1016/S0140-6736(22)01692-0

Article  PubMed  Google Scholar 

Cutolo M, Soldano S, Smith V (2019) Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev Clin Immunol 15(7):753–764. https://doi.org/10.1080/1744666X.2019.1614915

Article  CAS  PubMed  Google Scholar 

Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S et al (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44(6):1351–1358. https://doi.org/10.1002/1529-0131(200106)44:6%3c1351::AID-ART227%3e3.0.CO;2-I

Article  CAS  PubMed  Google Scholar 

van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB (1996) Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 35(4):364–372. https://doi.org/10.1093/rheumatology/35.4.364

Article  PubMed  Google Scholar 

Mendoza FA, Nagle SJ, Lee JB, Jimenez SA (2012) A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 39(6):1241–1247. https://doi.org/10.3899/jrheum.111229

Article  CAS  PubMed  Google Scholar 

Le EN, Wigley FM, Shah AA, Boin F, Hummers LK (2011) Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 70(6):1104–1107. https://doi.org/10.1136/ard.2010.142000

Article  CAS  PubMed  Google Scholar 

Barnes H, Holland AE, Westall GP, Goh NS, Glaspole IN (2018) Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database Syst Rev 1(1):CD010908. https://doi.org/10.1002/14651858.CD010908.pub2

Article  PubMed  Google Scholar 

Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327–1339. https://doi.org/10.1136/annrheumdis-2016-209909

Article  PubMed  Google Scholar 

Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666. https://doi.org/10.1056/NEJMoa055120

Article  CAS  PubMed  Google Scholar 

Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P et al (1993) Skin thickness score in systemic sclerosis (SSc): An assessment of inter-observer variability in three independent studies. J Rheumatol 20:1892–1896

CAS  PubMed  Google Scholar 

Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG (2002) Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 29(2):298–304

CAS  PubMed  Google Scholar 

Namas R, Tashkin DP, Furst DE, Wilhalme H, Tseng CH, Roth MD et al (2018) Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo‐controlled trials. Arthritis Care Res (Hoboken) 70(3):439–444. https://doi.org/10.1002/acr.23282

Article  CAS  PubMed  Google Scholar 

Nadashkevich O, Davis P, Fritzler M, Kovalenko W (2006) A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 25(2):205–212. https://doi.org/10.1007/s10067-005-1157-y

Article  CAS  PubMed  Google Scholar 

Valentini G, Paone C, La Montagna G, Chiarolanza I, Menegozzo M, Colutta E et al (2006) Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease. Scand J Rheumatol 35(1):35–38. https://doi.org/10.1080/03009740510026896

Article  CAS  PubMed  Google Scholar 

de Macedo PA, Borges CTL, de Souza RBC (2009) Cyclophosphamide: Effective in the treatment of severe cutaneous involvement in systemic sclerosis. Rev Bras Reumatol 49(3):265–275

Article  Google Scholar 

Herrick AL, Lunt M, Whidby N, Ennis H, Silman A, McHugh N et al (2010) Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol 37(1):116–124. https://doi.org/10.3899/jrheum.090668

Article  PubMed  Google Scholar 

Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J et al (2011) Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 378(9790):498–506. https://doi.org/10.1016/S0140-6736(11)60982-3

Article  CAS  PubMed  Google Scholar 

Domiciano DS, Bonfá E, Borges CT, Kairalla RA, Capelozzi VL, Parra E et al (2011) A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma. Clin Rheumatol 30(2):223–229. https://doi.org/10.1007/s10067-010-1493-4

Article  PubMed  Google Scholar 

Ostojic P, Damjanov N (2011) Effects of micronutrient antioxidants (alpha-tocopherol and ascorbic acid) on skin thickening and lung function in patients with early diffuse systemic sclerosis. Rheumatol Int 31(8):1051–1054. https://doi.org/10.1007/s00296-010-1398-1

Article  CAS  PubMed  Google Scholar 

Pérez Campos D, Estévez Del Toro M, Peña Casanovas A, González Rojas PP, Morales Sánchez L, Gutiérrez Rojas AR (2012) Are high doses of prednisone necessary for treatment of interstitial lung disease in systemic sclerosis? Reumatol Clin 8(2):58–62. https://doi.org/10.1016/j.reuma.2011.11.006

Article  PubMed  Google Scholar 

Poormoghim H, Rezaei N, Sheidaie Z, Almasi AR, Moradi-Lakeh M, Almasi S et al (2014) Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement - a retrospective study. Rheumatol Int 34(12):1691–1699. https://doi.org/10.1007/s00296-014-3026-y

Article  CAS  PubMed  Google Scholar 

van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J et al (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311(24):2490–2498. https://doi.org/10.1001/jama.2014.6368

Article  CAS  PubMed  Google Scholar 

Balbir-Gurman A, Yigla M, Guralnik L, Hardak E, Solomonov A, Rozin AP et al (2015) Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience. Isr Med Assoc J 17(3):150–156

PubMed  Google Scholar 

Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708–719. https://doi.org/10.1016/S2213-2600(16)30152-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L et al (2017) Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis 76(7):1207–1218. https://doi.org/10.1136/annrheumdis-2016-210503

Article  CAS  PubMed  Google Scholar 

Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P (2018) Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford) 57(12):2106–2113. https://doi.org/10.1093/rheumatology/key213

Article  CAS  PubMed  Google Scholar 

Bruni C, Tashkin DP, Steen V, Allanore Y, Distler O, Grotts J et al (2020) Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials. Clin Exp Rheumatol 38(Suppl 125 3):161–168

PubMed  Google Scholar 

Kersten BE, den Broeder N, van den Hoogen FHJ, Knaapen-Hans HAK, van den Ende CHM, Vonk MC (2020) Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosis. Rheumatology (Oxford) 59(7):1550–1555. https://doi.org/10.1093/rheumatology/kez487

Article  CAS  PubMed  Google Scholar 

Pan J, Dong F, Ma L, Zhao C, Qin F, Wen J et al (2023) Therapeutic effects of thalidomide on patients with systemic sclerosis-associated interstitial lung disease. J Scleroderma Relat Disord 8(3):231–240. https://doi.org/10.1177/23971983231180077